Fact-checked by Grok 2 weeks ago

Ammonium bituminosulfonate

Ammonium bituminosulfonate, also known as ichthammol, is a complex organic ammonium salt derived from the sulfonation and neutralization of dark , appearing as a syrupy black liquid with a characteristic odor. It is produced through of sulfur-rich bituminous , followed by sulfonation with and neutralization with , resulting in a water-soluble compound containing over 10.5% organically bound as per standards. First introduced in the by dermatologist Paul Gerson Unna for treating eczematous , it has been marketed since 1925 as a "drawing " under brand names like Ichtholan for its ability to promote skin permeability and healing. This compound exhibits multifaceted pharmacological properties, including anti-inflammatory, antibacterial, antifungal, and anti-eczematous effects, making it effective against pathogens such as and . Its mechanism involves interacting with epidermal proteins like and to loosen the skin barrier in a concentration-dependent manner, enhancing permeability without altering expression, as demonstrated on 3D skin models. Clinically, ammonium bituminosulfonate is applied topically in concentrations ranging from 0.5% to 50% to treat inflammatory skin disorders such as , , seborrheic eczema, , boils, furuncles, and abscesses, often in ointment form to draw out infections and reduce inflammation. It is also used in combination therapies for conditions like anal fissures, , and , and has been available over-the-counter since at least 1938. Despite its long history of use in , data on contraindications, adverse effects, and remain limited, with possible allergic reactions noted in sensitive individuals; caution is advised during and due to insufficient evidence. The compound's poor in fatty oils, , and further defines its formulation primarily as aqueous or emulsified preparations for targeted application.

History and Production

Discovery and Development

Ammonium bituminosulfonate, commercially known as Ichthyol, traces its origins to late 19th-century experiments in Germany involving the distillation of sulfur-rich bituminous shale. In 1879, chemist Rudolf Schröter encountered oil shale deposits during geological excursions in the Tyrolean Karwendel Mountains, where local residents had traditionally applied the material to soothe skin irritations and wounds. Schröter pioneered a method to distill the shale oil and subsequently sulfonate it with sulfuric acid, yielding a dark, viscous ammonium salt with potential therapeutic value derived from fossil shale oils. Initial testing emphasized veterinary applications, where the substance proved effective against skin infections, abscesses, and inflammatory conditions in such as and , prompting further refinement for broader medicinal use. By 1882, Schröter introduced the product to the market, leading to the formal establishment of the Ichthyol-Gesellschaft, or Cordes, Hermanni & Co., in in 1884, in partnership with merchants Heinrich Cordes and Gustav Hermanni. This company focused on scaling production and commercialization, naming the compound "Ichthyol" after the Greek term for to evoke its ancient organic origins in . The first medical publications highlighting its anti-inflammatory properties appeared in the 1880s, notably through the efforts of dermatologist Paul Gerson Unna, who documented successful treatments for eczematous and psoriatic skin conditions in clinical reports. Early recognition centered on its topical efficacy in reducing and promoting healing, transitioning from veterinary trials to human . Key milestones included international filings, such as a 1901 U.S. for the sulfonation process, which facilitated expansion into global markets by the early 1900s, solidifying Ichthyol's status as a staple in therapeutic ointments.

Manufacturing Process

The manufacturing process of ammonium bituminosulfonate, commonly known as Ichthammol, begins with the of sulfur-rich bituminous schists, a type of fossilized containing organically bound . These raw materials are heated in the absence of air at temperatures starting from 300°C, typically up to 450°C, to release a crude distillate through low-temperature . The resulting , which contains approximately 15% in organically combined form, undergoes sulfonation using concentrated to introduce groups, forming sulfonated bituminous compounds. This step is critical for enhancing the water solubility and therapeutic properties of the product, yielding a mixture of . Subsequently, the sulfonated oil is neutralized with , converting the acids into their salts and producing a dark, viscous, water-soluble semi-solid. Purification steps, including and removal of unreacted oils and impurities, follow to ensure product quality. In modern production, the entire process is refined under (GMP) conditions to maintain consistency, with measures verifying parameters such as total content, which must be at least 10% in the final product. The concentrated ammonium bituminosulfonate is then standardized, typically to 10% or 20% for incorporation into ointments, depending on the formulation requirements.

Chemical Composition and Properties

Molecular Structure and Components

Ammonium bituminosulfonate, also known as ichthammol, is classified as a complex mixture of salts of sulfonic acids derived from the sulfonation of hydrocarbons obtained from bituminous . This heterogeneous composition arises from the natural variability of the source material, which consists of sulfur-rich bituminous schists formed from ancient deposits. The key components include sulfonated polycyclic aromatic compounds, such as alkylbenzenes, thiophenes, and other sulfonated arenes, along with ammonium bituminosulfonates and minor nitrogen- and oxygen-containing functional groups introduced during sulfonation and neutralization processes. Due to its natural origin and processing, no single molecular formula can fully represent the substance; instead, it is characterized as a mixture of high-molecular-weight organic compounds with a rigid network structure. Approximate empirical representations from elemental analysis include C_{28}H_{36}S_5O_6(NH_4)_2, reflecting an average composition rather than discrete molecules. The total sulfur content is standardized at a minimum of 10.0% according to USP specifications, underscoring the sulfonated nature of the fractions. Characterization of the sulfonated fractions relies on analytical methods such as (NMR) , (IR) , and to identify structural features and compositional variability. For instance, NMR and have been used to detect specific sulfonated aromatic classes and degrees of , while IR confirms the presence of groups and aromatic rings. These techniques highlight the complexity, with studies identifying up to 14 classes of sulfonated aromatic compounds varying in .

Physical and Chemical Characteristics

Ammonium bituminosulfonate appears as a dark to black, viscous or sticky semi-solid with a strong, characteristic tar-like odor. This reddish-brown to brownish-black substance is derived from sulfonated bituminous material, contributing to its bituminous scent and texture. It exhibits high solubility in , exceeding 100 mg/mL at 64°F (18°C), and is miscible with , making it suitable for aqueous and glycerin-based formulations. The compound is slightly soluble in (96%) and fatty oils, but insoluble in non-polar solvents such as or concentrated hydrocarbons. Aqueous solutions display a of 6.0 to 7.5, reflecting mild acidity from the groups in its composition. Under normal conditions of and , ammonium bituminosulfonate remains chemically stable, but it decomposes at elevated temperatures above approximately 140°C, releasing toxic fumes including oxides, oxides, and . Its specific gravity ranges from 1.04 to 1.085 at 20°C, and the is 1.44 to 1.46, properties that aid in its identification and handling in pharmaceutical preparations. Sealed storage is recommended to prevent contamination due to its viscous nature and solubility characteristics.

Therapeutic Applications

Human Medical Uses

Ammonium bituminosulfonate, also known as ichthammol, serves as a topical agent primarily in for treating inflammatory skin disorders such as eczema, , , boils (furunculosis), and minor burns. Recent studies have also explored its use in , with a 2020 case series reporting improvement in over 90% of patients, and in mild plaque , demonstrating efficacy in a 2025 study. It is formulated as ointments, creams, or solutions at concentrations of 10-20%, which help soothe , reduce , and promote in affected areas. In the treatment of furunculosis, ichthammol acts as a drawing salve to facilitate the of from boils, aiding in the resolution of localized infections without invasive procedures. It also functions as an emollient for dry skin conditions, particularly in atopic eczema, where it hydrates and protects barrier to alleviate dryness and itching. The European Dermatology Forum guidelines recommend ichthammol as a useful addition to basic emollient therapy for mild atopic eczema, especially in cases of corticophobia or when topical corticosteroids are avoided. Administration typically involves applying a thin layer to the cleansed affected area using a , once or twice daily, for 1-2 weeks or until symptoms resolve, without rubbing or massaging the site. It is often combined with oxide in paste bandages to enhance soothing effects and manage chronic lichenified conditions like eczema and .

Veterinary Uses

Ammonium bituminosulfonate, commonly known as ichthammol, is widely applied in for treating dermatological conditions and infections in animals such as , , and . In , it serves as a drawing agent for hoof abscesses and thrush, helping to soften the and promote drainage of , while also addressing irritations from insect bites or . In , it is used for minor infections, abscesses, and hot spots (acute moist ), reducing and aiding in the resolution of localized swellings. For , applications include treatment of , furunculosis (boils), and udder inflammations, particularly in food-producing animals. Formulations typically consist of 20% ichthammol in an ointment base, such as and petrolatum, functioning as a drawing for poultices on hooves or wounds, or applied directly as rubs and under bandages to enhance penetration and protect the site. In equine practice, it is often packed into the frog sulci for thrush or applied to the sole in cases as an adjunct to reduce and support health, with loose wrappings recommended to maintain moisture. Dosage guidelines from veterinary sources specify topical application once or twice daily to affected areas, avoiding excessive heat to prevent irritation. Veterinary literature supports its efficacy through historical case studies and experimental models; for instance, early reports documented resolution of abscesses in within a few days using undiluted ichthammol applied 2-3 times daily for cases of 1-2 days duration, and eczema in dogs with 5-10% solutions achieving cures in 83% of cases. More recent investigations in animal models demonstrate that pale ichthammol accelerates epithelialization and reduces in impaired wounds, attributing this to its and antibacterial properties. These findings align with its traditional role in promoting faster recovery from equine abscesses and skin lesions, though controlled clinical trials remain limited.

Pharmacology and Mechanism of Action

Pharmacological Effects

Ammonium bituminosulfonate, commonly known as ichthammol, exerts anti-inflammatory effects primarily through the inhibition of 5-lipoxygenase (5-LOX) activity in human polymorphonuclear neutrophils, leading to reduced synthesis of leukotrienes such as (LTB4), which are key mediators of . This inhibition is dose-dependent and contributes to the suppression of inflammatory responses at the cellular level. Additionally, related sulfonated derivatives, such as sodium bituminosulfonate, have been shown to modulate the generation of pro-inflammatory mediators from neutrophils, including (ROS) and LTB4, thereby attenuating in skin conditions. The compound demonstrates properties with broad-spectrum activity against , such as those implicated in infections, owing to the disruptive effects of its sulfonated components on bacterial processes. It also exhibits antimycotic effects against certain fungi, enhancing its utility in treating mixed microbial disorders through bactericidal and fungicidal actions. Other pharmacological actions include effects that loosen the intercellular matrix of the in a concentration-dependent manner, increasing permeability and facilitating the of in deep inflammations. It possesses properties that alleviate itching and mild effects that reduce local , largely secondary to its anti-inflammatory activity. Furthermore, ichthammol acts as an osmotic drawing agent in abscesses, promoting the resolution of localized collections through hyperosmolar effects. Pharmacokinetically, when applied topically, ammonium bituminosulfonate exhibits poor systemic absorption, with negligible amounts entering the bloodstream to avoid widespread effects, and is primarily retained in layers for localized action. This profile supports its use as a targeted topical agent with minimal risk of systemic exposure under normal conditions.

Clinical Evidence and Studies

Early clinical evidence for ammonium bituminosulfonate, commonly known as ichthammol, stems from 19th- and 20th-century observational reports documenting its topical application for various dermatological conditions, including eczematous dermatitis, , leg ulcers, seborrheic dermatitis, and furuncles. These reports, based on empirical use since its introduction in the late 1800s, highlighted its role as a drawing salve with purported and properties, though lacking rigorous controls. In modern , remains primarily anecdotal and small-scale, with few randomized controlled trials (RCTs). A and case series evaluated topical 10% ichthammol for (HS), reporting symptom improvement in observational cases, but noted a scarcity of high-quality studies across , including none specifically for abscesses, boils, or blisters despite traditional use. For atopic eczema, ichthammol at 1% concentration or in paste bandages is considered effective and safe based on clinical guidelines and reviews, supporting its role in reducing and promoting skin barrier function. A 2022 in vitro study using 3D skin models demonstrated ammonium bituminosulfonate's concentration-dependent loosening of the stratum corneum's intercellular matrix, with reduced expression of and at higher doses (50%), alongside influences on degradation pathways via and inhibition, suggesting anti-inflammatory mechanisms. However, evidence for systemic or oral applications is limited, with no substantial trials identified. Overall, evidence levels are stronger for topical uses in inflammatory conditions like eczema and , derived from historical observations and small modern studies, but gaps persist due to the absence of large-scale double-blind RCTs. Ongoing investigations focus on molecular targets, such as modulation in inflammatory pathways, to better elucidate efficacy.

Safety, Side Effects, and Availability

Adverse Effects and Contraindications

Ammonium bituminosulfonate, commonly known as ichthammol, is generally well-tolerated when used topically, with adverse effects primarily limited to local reactions. Common side effects include mild irritation, redness, itching, burning, or swelling at the application site, often indicative of . These reactions, such as , are rare, occurring in isolated cases rather than at high incidence rates. Systemic effects are uncommon due to the compound's low absorption. Contraindications for ammonium bituminosulfonate include known to ichthammol or sulfonated derivatives, as this may provoke severe allergic responses. It should not be applied to open wounds with high , deep lesions, or near the eyes and mucous membranes to prevent irritation or unintended exposure. Precautions are advised during and due to limited data on safety, with healthcare providers recommending consultation before use; no formal has been established, but caution is warranted. Use in children under 2 years should be supervised or avoided without medical advice, given the lack of pediatric-specific studies. Potential interactions may occur with oxidizing agents, though clinical reports are sparse; compatibility testing is suggested for compounded formulations. Toxicity profiles indicate low acute risk, with an oral LD50 exceeding 10 g/kg in rats, supporting its in topical applications. Long-term studies in animal models have shown no evidence of carcinogenicity, with zero incidence of carcinomas observed in mice treated with ichthammol compared to tar-containing alternatives.

Regulatory Status and Commercial Availability

Ammonium bituminosulfonate, commonly known as ichthammol, is classified as an over-the-counter (OTC) topical agent for skin protectant uses, such as treating minor skin irritations, boils, and drawing out splinters, under the FDA's regulatory for non-prescription drugs. It is included in the FDA's list of active ingredients for OTC skin protectant products, though some formulations carry disclaimers noting that the FDA has not fully evaluated their and due to the grandfathered status of certain older monographs. , ichthammol is registered as a substance under REACH and is available for topical use in and pharmaceuticals, with higher concentrations (e.g., above 10%) often requiring a prescription in select member states like , while lower-strength products are sold OTC in pharmacies. No major regulatory bans have been imposed globally as of 2025, and it remains compliant with current EU regulations for applications. Commercially, ammonium bituminosulfonate is formulated primarily as ointments containing 10% to 20% ichthammol, alongside creams, gels, and occasional shampoos for dermatological and veterinary applications. Prominent brands include Ichthyol® from the Ichthyol-Gesellschaft and generics such as Ichthammol Ointment and MG217 Drawing Salve, which are marketed for and drawing effects on conditions. is centered in by the family-owned Ichthyol-Gesellschaft Cordes, Hermanni & Co. ( & Co.) KG, which adheres to GMP standards and supplies raw materials derived from sulfonated for global pharmaceutical and cosmetic manufacturers. The compound is widely available in retail pharmacies, veterinary supply stores, and online platforms like , with no significant supply disruptions reported through 2025. It appears in select national essential medicines lists, such as India's 2011 list for topical ear and skin treatments, supporting its accessibility for basic dermatological care in resource-limited settings, though it is not on the WHO Model List of .